On this page:
WHAT IS IXCHIQ®?
IXCHIQ® Chikungunya vaccine (live) provides a strong and persistent immune response against disease caused by Chikungunya virus (CHIKV) with one dose.1,2
IXCHIQ® INDICATION
IXCHIQ® is licensed for active immunisation against CHIKV for adults aged 18–59 years.1
It is recommended to continue personal protection measures against mosquito bites after vaccination.1
IXCHIQ® CONTRAINDICATIONS
IXCHIQ® should not be given to individuals who are immunodeficient, immunosuppressed, suffer from hypertension, cardiovascular disease, diabetes mellitus, chronic kidney disease (CKD), or with a hypersensitivity to any component of the vaccine.1
Caution is advised when administering the vaccine to individuals with two or more underlying chronic health conditions.1
For more information about special warnings and precautions for use, please refer to the Summary of Product Characteristics.
IXCHIQ® KEY FACTS
WORLD-FIRST VACCINE AGAINST CHIKV
IXCHIQ® was the world’s first vaccine licensed to help protect against chikungunya.3,4
EFFECTIVE LIVE VACCINE DESIGN
Developed using a well-established, live-attenuated vaccine technology that can help to induce long-lasting immunity.5
POWERFUL PROTECTION
98.9% of clinical trial participants reached seroresponse threshold 28 days after vaccination; 94.5% maintained seroresponse rate four years after vaccination.6,7
GENERALLY WELL TOLERTAED IN CLINICAL STUDIES
IXCHIQ® was shown to be generally well tolerated across clinical trials involving more than 3500 adults.6
SINGLE DOSE ADMINISTRATION
IXCHIQ® is administered in one injectable dose, no later than 30 days prior to travel.1
PRODUCT CHARACTERISTICS
IXCHIQ® is supplied as a powder and solvent for solution for injection. The vaccine consists of a vial containing lyophilised powder and a pre-filled syringe containing sterile water for injection. The two components must be reconstituted before administration to produce a 0.5 mL solution for intramuscular injection.6
After reconstitution, each 0.5 mL dose contains live, attenuated chikungunya virus (Δ5nsP3 strain) produced in Vero cells, with a potency of not less than 3.0 log10 TCID50 (50% tissue culture infectious dose).6
The powder contains the following excipients: sucrose, D-sorbitol, L-methionine, trisodium citrate di-hydrate, magnesium chloride, di-potassium hydrogen phosphate, potassium di-hydrogen phosphate and recombinant human albumin. The solvent is sterile water for injections.6
VACCINE STORAGE AND HANDLING
The vial and syringe should be stored in a refrigerator at 2–8 °C6
Do not freeze6
Unopened vial has a shelf life of two years6
All IXCHIQ® components should be stored in the original carton to protect from light6
The reconstituted IXCHIQ® vaccine is stable for two hours when stored either refrigerated (2°C to 8°C) or at room temperature (15–25 °C), after which it must be discarded6
LEARN MORE ABOUT IXCHIQ®
Delve deeper into the product features, clinical findings and dosing recommendations.
IXCHIQ®▼powder and solvent for solution for injection
CLINICAL DATA
Explore the latest clinical data on the efficacy and safety profile of IXCHIQ®.
IXCHIQ®▼powder and solvent for solution for injection
DOSING & ADMINISTRATION
IXCHIQ® is administered as a convenient single injectable dose.
References
- IXCHIQ®. Patient Information Leaflet. March 2026. Available at: https://www.medicines.org.uk/emc/product/100652/pil.100652. Accessed: August 2026.
- Valneva SE. Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®. September 2025. Available at: https://valneva.com/wp-content/uploads/2025/09/2025_09_30_IXCHIQ_4Y_Persistence_PR_EN_Final.pdf. Accessed: August 2026.
- BBC News. Chikungunya vaccine: US approves first shot against mosquito-borne virus. November 2023. Available at: https://www.bbc.co.uk/news/world-asia-67376584. Accessed: August 2026.
- Valneva SE. Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®. February 2025. Available at: https://valneva.com/press-release/valneva-receives-marketing-authorization-in-the-uk-for-the-worlds-first-chikungunya-vaccine-ixchiq. Accessed: August 2026.
- Tang Y, Li Y, Cai X, Yin X. Viral Live‐Attenuated Vaccines (LAVs): Past and Future Directions. Adv Sci (Weinh). 2024;12(3):2407241.
- IXCHIQ®. Summary of Product Characteristics. March 2026. Available at: https://www.medicines.org.uk/emc/product/100652/smpc. Accessed: August 2026.
- Sattler N, Scheiblauer S, Hochreiter R, Kosulin K, Buerger V. Chikungunya virus-neutralizing antibody persistence four years after single-dose vaccination with VLA1553 (IXCHIQ®). Vaccine. 2026;88:128787.
UK-IXC-2600005 August 2026